NTM Info & Research (NTMir), the national nonprofit organization advocating on behalf of patients with nontuberculous mycobacterial (NTM) lung disease, applauds the European Commission’s decision to grant marketing authorization for ARIKAYCE® Liposomal 590 mg Nebuliser Dispersion (“ARIKAYCE”) for the treatment of nontuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium complex (MAC) in adults with non-cystic fibrosis bronchiectasis who have limited treatment options.
“For more than a decade, Insmed has worked tirelessly e to bring this treatment to fruition for patients everywhere with NTM lung disease,” said NTMir president, Amy Leitman. “This authorization represents another major milestone in the fight against this disease, and another victory for Insmed as well as the physicians and researchers who have worked for so long to help patients.”
“Patients in particular have been asking for more inhaled therapies to treat the infection without causing harm to the rest of their bodies,” he added. “We are grateful that ARIKAYCE® will be available to more patients who so desperately need more options for treatment.”
About NTM Lung Disease
NTM lung disease is a devastating chronic illness associated with increased rates of morbidity and mortality, and there is an increasing prevalence of NTM lung disease in the United States and around the world. NTM lung infection can cause or worsen significant respiratory damage, such as bronchiectasis. Patients with NTM lung disease may experience symptoms including fever, weight loss, cough, lack of appetite, night sweats, blood in the sputum, and fatigue. Treatment for NTM lung disease consists of three or more antibiotics for a minimum of 12-18 months, often with harsh side effects.
About NTMir
NTM Info & Research (NTMir) is a 501(c)(3) non-profit organization formed on behalf of patients with pulmonary nontuberculous mycobacterial (NTM) disease for patient support, medical education and research. NTMir serves patients, healthcare providers, and researchers concerned with NTM. As a national organization, we can advance a broad agenda more successfully than individuals or institutions alone. Our voice is that of the patients, providers and researchers who comprise our collective constituency. For more information, visit our website at www.ntminfo.org.
About Insmed
Insmed Incorporated is a global biopharmaceutical company focused on the unmet needs of patients with rare diseases. For more information, visit www.insmed.com.
